• Home
• RNAi Delivery Solution
  • Traversa's RNAi Delivery Technology (PTD-DRBD)
• About Traversa Therapeutics
• Newsroom
• Investor Relations
• Contact Us
  
• Legal

• March 25, 2010 Traversa Therapeutics and sanofi-aventis enter into a research agreement for the development of Traversa's RNAi delivery technology
• January 6, 2010 Traversa Appoints Curt W. Bradshaw, Ph.D. as VP of Research & Development
• April 2, 2009 Traversa Therapeutics Completes Series B Financing. Company continues to advance toward the clinic with novel RNA interference technologies.
• March 24, 2009 Traversa Therapeutics announces appointment of William G. Kaelin, Jr., M.D. and Yitzhak Tor, Ph.D. to the company's scientific advisory board
• February 4, 2008 Traversa Raises $2M to Advance RNAi Delivery in Angel-Led Series A Financing